Epidemiology and outcomes of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1695-1703

  Horn, David L ^a,j   Neofytos, Dionissios ^a,b   Anaissie, Elias J ^c   Fishman, Jay A ^d   Steinbach, William J ^e   Olyaei, Ali J ^f   Marr, Kieren A ^b   Pfaller, Michael A ^g   Chang, Chi Hsing ^h   Webster, Karen M ⁱ  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF IOWA HEALTH CARE   (United States)

^h Info Spectrum   (Canada)

ⁱ EBM Consulting   (Canada)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; CORTICOSTEROID; ECHINOCANDIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; MICAFUNGIN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA GUILLERMONDII; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CHILD; DATA BASE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE ANTIFUNGAL THERAPY ALLIANCE REGISTRY; REGISTER; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; ECHINOCANDINS; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66949118944     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599039     Document Type: Article

References (45)

1. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo- controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-8.
2. Peres-Bota D, Rodriguez-Villalobos H, Dimopoulos G, Melot C, Vincent JL. Potential risk factors for infection with Candida spp. in critically ill patients. Clin Microbiol Infect 2004; 10:550-5.
3. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 1995; 20:1531-4.
4. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Williston Park) 2004; 18(Suppl 13):9-14.
5. Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41:521-6.
6. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-30.
7. Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005;41:1455-60.
8. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634-43.
9. Blumberg HM, Jarvis WR, Soucie JM, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001;33:177-86.
10. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of can- didiasis. Clin Infect Dis 2004;38:161-89.
11. Morgan J, Meltzer MI, Plikaytis BD, et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005; 26:540-7.
12. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length ofstay. Arch Intern Med 1988; 148:2642-5.
13. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-7.
14. Chen S, Slavin M, Nguyen Q, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12:1508-16.
15. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P. Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003;9:985-90.
16. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM- 2004 study. Haematologica 2006;91:1068-75.
17. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998; 104:238-45.
18. Nieto-Rodriguez JA, Kusne S, Manez R, et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 223:70-6.
19. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in non- neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23:23-30.
20. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999;28:1071-9.
21. Ostrosky-Zeichner L. New approaches to the risk of Candida in the intensive care unit. Curr Opin Infect Dis 2003; 16:533-7.
22. Colombo AL, Nucci M, Park BJ, et al. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol 2006;44:2816-23.
23. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005;41:1232-9.
24. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25-31.
25. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5.
26. Horn D, Neofytos D, Fishman J, et al. Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. Eur J Clin Microbiol Infect Dis 2007; 26:907-14.
27. Horn DL, Fishman JA, Steinbach WJ, et al. Presentation of the PATH Alliance(R) registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007;59:407-14.
28. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
29. Marchetti O, Bille J, Fluckiger U, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004;38:311-20.
30. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:309-17.
31. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20:133-63.
32. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274-7.
33. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993;37:1847-9.
34. Yamamura DL, Rotstein C, Nicolle LE, Ioannou S. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society. Cmaj 1999; 160:493-9.
35. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifun- gal resistance. Am J Med 1996; 100:617-23.
36. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24:1122-8.
37. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J 1998; 17:504-8.
38. Bassetti M, Righi E, Tumbarello M, Di Biagio A, Rosso R, Viscoli C. Candida infections in the intensive care unit: epidemiology, risk factors and therapeutic strategies. Expert Rev Anti Infect Ther 2006; 4:875-85.
39. Dotis J, Evdoridou J, Kremenopoulos G, Roilides E. Survey ofneonatal candidiasis in Greece. Eur J Clin Microbiol Infect Dis 2005; 24:749-52.
40. Rodriguez D, Almirante B, Park BJ, et al. Candidemia in neonatal intensive care units: Barcelona, Spain. Pediatr Infect Dis J 2006;25:224-9.
41. Vigouroux S, Morin O, Moreau P, Harousseau JL, Milpied N. Can- didemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center. Haematologica 2006; 91:717-8.
42. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503-35.
43. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366:1435-42.
44. Klevay MJ, Horn DL, Neofytos D, Pfaller MA, Diekema DJ; for the PATH Alliance. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn Microbiol Infect Dis 2009 (Epub ahead of print).
45. Horn D, Neofytos D. Contemporary patterns in the use of antifungal agents in the treatment of invasive fungal infections: perspectives from registries and databases. Curr Fungal Infect Rep 2007; 1:72-78.